Abstract:Background and Objective In amyotrophic lateral sclerosis (ALS), progressive weakness significantly limits the ability to exercise. However, measurements of the impaired exercise function and their practical value to assess disease progression in ALS are scarce. Cardiopulmonary exercise testing (CPET) is a non-invasive accurate method used to comprehensively quantify exercise physiology in a variety of diseases. This study aimed to evaluate the clinical value of CPET and to explore its association with disease severity and prognosis prediction in ALS. Methods A total of 319 participants were enrolled in this 3-year prospective study. After strict quality control, 109 patients with ALS and 150 age- and sex-matched healthy controls were included with comprehensive clinical assessment and follow-ups. The incremental ramp protocol for symptom-limited CPET was applied in both groups. The exercise physiology during peak effort exercise was systematically measured, including the overall aerobic capacity of exercise (VO 2 peak) and the respective capacity of the exercise-involved organs [cardiac response (heart rate peak—HR peak), ventilatory efficiency (VE/VCO 2 slope), breathing economy (VE/VO 2 peak), and other relevant parameters]. Disease severity and progression were evaluated using recognized scales. Survival was monitored with regular follow-ups every 6 months. Results Decreased exercise capacity (VO 2 peak < 16 ml/kg/min) occurred more frequently in patients with ALS than in controls (44.95% vs. 9.33%, p < 0.01). In patients with ALS, the average VO 2 peak (16.16 ± 5.43 ml/kg/min) and HR peak [135 (112–153) bpm] were significantly lower ( p < 0.01) than in controls [22.26 ± 7.09 ml/kg/min; 148 (135–164) bpm], but the VE/VCO 2 slope was significantly higher [28.05 (25.03–32.16) vs. 26.72 (24.37–29.58); p = 0.03]. In patients with ALS, the VO 2 peak and HR peak were significantly correlated with disease severity and progression scores ( p < 0.05). Survival analyses revealed the VO 2 peak and HR peak as protective indicators while the VE/VO 2 peak as a detrimental indicator for the prognostic prediction in ALS (HR = 0.839, p = 0.001; HR = 0.967, p < 0.001; HR = 1.137, p = 0.028, respectively). Conclusion Our prospective study quantified the significantly decreased exercise capacity in ALS through non-invasive CPET. The impaired VO 2 peak and HR peak closely correlated with disease severity and independently predicted a worse prognosis. Our findings identified the clinical value of CPET as an objective indicator of disease progression in ALS.

Decreased Cardiac Autonomic Activity and Increased Sympathetic Vascular Control in Advanced Stages of Amyotrophic Lateral Sclerosis

Baroreflex stimulation shows impaired cardiovagal and preserved vasomotor function in early-stage amyotrophic lateral sclerosis

Amygdala Abnormalities Are Related to Anxiety in Patients with Sporadic Amyotrophic Lateral Sclerosis

Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis: a prospective longitudinal cohort study

Autophagy and Its Comprehensive Impact on ALS

Peripheral immunity relate to disease progression and prognosis in amyotrophic lateral sclerosis

Early Axonal Dysfunction of the Peripheral Nervous System Influences Disease Progression of ALS: Evidence From Clinical Neuroelectrophysiology

Peripheral and Central Nervous System Immune Response Crosstalk in Amyotrophic Lateral Sclerosis

Early Axonal Dysfunction of the Peripheral Nervous System Influences Disease Progression of ALS: Evidences From Clinical Neuroelectrophysiology

Different observation period of exercise training in amyotrophic lateral sclerosis patients: A meta-analysis

Amygdala abnormalities across disease stages in patients with sporadic amyotrophic lateral sclerosis

Exercise Physiology Impairments of Patients With Amyotrophic Lateral Sclerosis: Cardiopulmonary Exercise Testing Findings

Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies

Progress of disturbances in energy metabolism in amyotrophic lateral sclerosis

Effects of Diet on Adenosine Monophosphate-Activated Protein Kinase Activity and Disease Progression in an Amyotrophic Lateral Sclerosis Model

Static and dynamic alterations in the amplitude of low-frequency fluctuation in patients with amyotrophic lateral sclerosis

Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets

Regional Alterations in Cortical Thickness and White Matter Integrity in Amyotrophic Lateral Sclerosis.

Epidemiology and factors predicting survival of amyotrophic lateral sclerosis in a large Chinese cohort

Erythrocytes' surface properties and stiffness predict survival and functional decline in ALS patients

Multiple pathways of lipid dysregulation in amyotrophic lateral sclerosis